Texas Based Aspira Women's Health Appoints Jane Pine Wood to Board of Directors

• Aspira Women's Health Inc. announced a new addition to its Board of Directors
• "Jane Pine Wood has joined the board, effective July 11, 2025"
• It is aimed at the creation of diagnostic and disease management devices for gynecologic diseases

Aspira Women's Health Inc., a women's health company based in Texas that develops and applies AI-based bioanalytical technologies, disclosed the appointment of Jane Pine Wood to its Board of Directors effective July 11, 2025.

The company, which is listed on QTCQB under the symbol AWHL, concentrates on providing sophisticated diagnostic and disease management solutions particularly for gynecologic ailments.

"We are excited to have Jane Pine Wood join our board of directors," stated Jack Fraser, Board Chairman at Aspira. "Jane's breadth of experience as a lawyer serving a broad range of healthcare providers—from clinical labs and hospitals to imaging centers and mental health clinics—makes her an excellent asset as we continue to evolve in revolutionizing women's healthcare."

Jane is presently Counsel at McDonald Hopkins, LLC and became so in 2024. Previously, she was Chief Legal Counsel for BioReference Health, LLC, and a leading clinical diagnostics lab specializing in oncology, urology, and women's health. Throughout close to 30 years at McDonald Hopkins, she was a key member in building one of the country's largest laboratory and pathology legal practices and has also served on the firm's Board of Directors.

Aspira Women's Health is committed to creating non-invasive, AI-driven diagnostics to aid in early detection and treatment of gynecologic diseases. The firm's OvaSuiteSM family of products, consisting of OvaWatch® and Ova1Plus®, provides physicians with the only end-to-end blood tests to evaluate the risk of ovarian cancer in women presenting with adnexal masses—an estimated 1.2 million women annually in the U.S. OvaWatch, possessing a 99 percent negative predictive value, can help exclude cancer when initial studies indicate a benign mass and spare them from unnecessary surgery. Ova1Plus combines two FDA-approved tests Ova1® and Overa® to evaluate malignancy risk in women undergoing surgery.

Aspira is also moving a pipeline of diagnostic products, such as tests that integrate microRNA, protein biomarkers, and patient information to enhance ovarian cancer detection rates. Furthermore, they are working on the first-ever non-surgical test for detecting endometriomas, a severe and prevalent type of endometriosis, with the ultimate aim of detecting all types of the disease regardless of severity and location.